Search this site

Medulloblastoma Medulloblastoma | Pathology, Imaging & Clinical Presentation This session on Medulloblastoma covers its clinical presentation, radiologic features, molecular subgroups, and surgical considerations, discussed through real neurosurgical cases. Medulloblastoma vs Ependymoma | Management, Surgical Principles & Key Differences The discussion emphasizes extent of resection, surgical goals, and common intraoperative considerations, along with side-by-side imaging features that help distinguish medulloblastoma from posterior fossa ependymoma. Medulloblastoma | Risk Stratification This session on Medulloblastoma Risk Stratification reviews how clinical, radiologic, surgical, and molecular factors are integrated to categorize patients into prognostic risk groups.

Aqueductal Stenosis Q. What is aqueductal stenosis? Aqueductal stenosis refers to narrowing or complete obstruction of the cerebral aqueduct (aqueduct of Sylvius), resulting in impaired cerebrospinal fluid flow from the third to the fourth ventricle. This leads to triventricular hydrocephalus, characterized by dilation of both lateral ventricles and the third ventricle with a normal-sized fourth ventricle. It is one of the most common causes of congenital obstructive hydrocephalus, accounting for up to 70 percent of congenital hydrocephalus. Q. What are the key radiological features of aqueductal stenosis? MRI (Gold standard): Triventricular hydrocephalus with dilation of the lateral and third ventricles Normal-sized fourth ventricle Loss of the normal aqueductal T2 flow void Tectal plate beaking, in which the superior colliculi are displaced anteriorly and inferiorly by the enlarged third ventricle, supporting a mechanical obstructive process Bowing of the third ventricular floor Widening of the third ventricle on sagittal images Normally, rapid pulsatile CSF flow within the aqueduct produces a signal dropout on T2-weighted images due to flow-related dephasing. In aqueductal stenosis, CSF flow is reduced or absent, abolishing this effect and causing the aqueduct to appear hyperintense on T2-weighted sequences. Post-contrast MRI is essential to exclude: Tectal plate glioma Brainstem tumor infiltration Quadrigeminal cistern arachnoid cyst Cine MRI (when available): Absence of pulsatile CSF flow through the aqueduct Useful for confirming functional obstruction when structural narrowing is subtle CT scan: Demonstrates triventricular hydrocephalus Fourth ventricle remains normal in size Useful in emergency settings Limited sensitivity for thin aqueductal membranes or webs Cranial ultrasound (infants): Dilation of lateral and third ventricles visualized through the open anterior fontanelle Useful as a screening tool in neonates and young infants Q. What are the etiologies of aqueductal stenosis? Aqueductal stenosis may be congenital or acquired. Congenital etiologies include isolated developmental narrowing of the aqueduct or association with other congenital anomalies such as Chiari malformation and neurofibromatosis. A severe inherited form is X-linked aqueductal stenosis due to L1CAM mutation, which predominantly affects males and often presents early with severe obstructive hydrocephalus. Characteristic associated features include: Adducted thumbs Spasticity Agenesis or hypoplasia of the corpus callosum Neurodevelopmental outcome is generally poorer compared with isolated congenital aqueductal stenosis. Identification is essential for genetic counseling, assessment of recurrence risk, and antenatal decision-making, as female carriers may be asymptomatic. Acquired etiologies include: Post-inflammatory: meningitis, tuberculous meningitis, intrauterine infections Post-hemorrhagic: neonatal intraventricular hemorrhage, subarachnoid hemorrhage with adhesions Neoplastic: tectal plate gliomas, brainstem astrocytomas Cystic: quadrigeminal cistern arachnoid cyst compressing the aqueduct Others: lipoma involving the aqueduct Q. How do you classify aqueductal stenosis? Aqueductal stenosis is classically classified according to the Russell classification, which describes four pathological patterns: Forking: Replacement of the normal aqueduct by multiple narrow channels due to partial fusion of the median fissure. Channels may rejoin or end blindly. Often associated with spinal dysraphism such as spina bifida and lipomyelocele. Periaqueductal gliosis: Characterized by proliferation of astrocytes and subependymal glial fibers narrowing the lumen, which can be reactive (post-inflammatory/hemorrhagic) or pressure-induced. True stenosis: Uniform congenital narrowing resulting from abnormal neuroepithelial folding. Septum formation: Occlusion of the distal aqueduct by a glial membrane, producing complete obstruction. Q. How do infants with aqueductal stenosis present? Infants typically present with features of obstructive hydrocephalus, as open sutures permit skull expansion. Common features include: Progressive macrocephaly Bulging, tense fontanelle Sunsetting of the eyes due to dorsal midbrain compression Engorged scalp veins Irritability, vomiting, and poor feeding Delayed developmental milestones due to cortical mantle thinning If untreated, long-term consequences include optic atrophy, seizures, and severe neurodevelopmental delay. Q. What are the clinical features in older children? After suture fusion, compensatory skull expansion is no longer possible and symptoms of raised intracranial pressure predominate: Persistent, often morning headaches Nausea and vomiting Papilledema Diplopia or blurred vision Gait imbalance Behavioral changes and cognitive slowing Decline in school performance Q. How does aqueductal stenosis present in adults? Adult aqueductal stenosis may present insidiously or acutely. Clinical features include: Chronic headaches Cognitive decline that may mimic normal-pressure hydrocephalus Magnetic gait and frequent falls Visual disturbance Urinary urgency or incontinence in advanced cases Endocrine dysfunction related to hypothalamic-pituitary compression is uncommon but may occur. Some patients remain clinically compensated for years until a secondary insult precipitates sudden intracranial pressure elevation and rapid deterioration. Q. What are the differential diagnoses of triventricular hydrocephalus? Important differential diagnoses include: Colloid cyst of the foramen of Monro: Obstruction at the foramina with patent aqueduct Quadrigeminal cistern arachnoid cyst: External compression of the aqueduct Posterior fossa tumors: Medulloblastoma, ependymoma, cerebellar tumors Intraventricular tumors: Central neurocytoma, choroid plexus tumors Post-meningitic or post-hemorrhagic adhesions: Particularly in neonates Q. How will you manage aqueductal stenosis? Management aims to restore cerebrospinal fluid circulation, address the underlying cause when present, and prevent long-term neurological sequelae. Treatment choice depends on patient age, ventricular anatomy, etiology, and basal cisternal patency. Endoscopic third ventriculostomy (ETV) is the preferred treatment for most patients, particularly older children and adults. It establishes an alternative CSF pathway between the third ventricle and the prepontine cistern. In appropriately selected patients, success rates range from 80 to 95 percent. Infants younger than six months have higher failure rates due to immature CSF absorption and poorly developed subarachnoid spaces. Aqueductoplasty is reserved for selected cases with short-segment membranous obstruction, such as septa or thin glial membranes. It is most effective in distal congenital membranous stenosis and less successful in long-segment gliotic narrowing or infiltrative tumors. Ventriculoperitoneal shunting is indicated when endoscopic procedures are unsuitable or have failed, particularly in: Infants younger than six months Multiloculated ventricles Extensive basal cisternal scarring Post-infectious or post-hemorrhagic obstruction Recurrent obstruction after endoscopic treatment Programmable valves help reduce overdrainage-related complications. Management of underlying pathology depends on etiology. Tectal plate gliomas are typically managed conservatively with CSF diversion alone. Arachnoid cysts may require cyst fenestration or ventriculo-cysto-cisternostomy. Tumoral posterior fossa obstruction requires tumor-directed therapy, with CSF diversion performed first if hydrocephalus is acute. Lumbar puncture is contraindicated due to the risk of transtentorial or tonsillar herniation. Q. What is the prognosis of aqueductal stenosis? Prognosis depends on age at presentation, etiology, and duration of hydrocephalus. Early intervention in infancy improves neurodevelopmental outcomes by preventing prolonged cortical mantle thinning. Isolated congenital aqueductal stenosis carries an excellent long-term prognosis, whereas associated anomalies worsen outcome. Adults often experience symptom reversal if treated early, although chronic cases may have residual gait or cognitive deficits. Recurrence is uncommon when obstruction is appropriately managed. Q. How do you diagnose aqueductal stenosis antenatally and what is the prenatal course? Aqueductal stenosis may be suspected antenatally when routine obstetric ultrasound shows progressive ventriculomegaly, typically involving the lateral and third ventricles. Serial antenatal scans demonstrating increasing ventricular dilatation over gestation support an obstructive mechanism rather than communicating hydrocephalus. Fetal MRI helps confirm aqueductal obstruction, assess cortical mantle thickness, and identify associated anomalies such as agenesis of the corpus callosum, Chiari malformation, or syndromic features including those suggestive of L1CAM-related hydrocephalus. Prognosis is influenced by the degree and progression of ventriculomegaly, preservation of the cortical mantle, and presence of associated CNS or genetic abnormalities. Q. What is the surgical anatomy and anatomical prerequisites for endoscopic third ventriculostomy (ETV)? ETV success depends on correct third ventricular floor anatomy recognition and patency of basal cisterns. The optimal perforation site is the tuber cinereum, typically located anterior to the mammillary bodies and posterior to the infundibular recess, where the third ventricular floor is thinnest. A well-developed prepontine cistern is necessary to allow effective CSF egress after ventriculostomy. Preoperative and intraoperative awareness of the basilar artery and its perforators is essential to prevent catastrophic vascular injury. Unfavorable anatomy includes a thickened or opaque third ventricular floor and obliterated basal cisterns, both of which reduce the likelihood of durable ETV success. Q. What are the failure patterns and clinical warning signs following ETV? ETV failure may be early or late. Early failure usually occurs within days to weeks and presents with persistent or recurrent features of raised intracranial pressure due to inadequate stoma creation, insufficient opening into the prepontine cistern, or impaired CSF absorption. Late failure may occur months to years later, most commonly due to gradual stoma closure, and can present with recurrent headache, vomiting, papilledema, or rapid neurological deterioration. Recurrent headache is often the earliest warning symptom. Long-term follow-up is essential because delayed and sometimes abrupt decompensation can occur even after an initially successful ETV.

Ependymomas - A Master Class Ependymoma | Basics This session on Ependymomas covers their clinical presentation, radiologic features, molecular classification, and surgical considerations, discussed through real neurosurgical cases. The discussion emphasizes anatomic and biologic differences across supratentorial, posterior fossa, and spinal ependymomas, highlighting how tumor location and molecular subtype influence prognosis, surgical strategy, and adjuvant treatment decisions. Posterior Fossa Ependymomas This session on Posterior Fossa Ependymomas examines their clinical presentation, radiologic features, molecular subgroups, and surgical considerations, discussed through real neurosurgical cases. The discussion emphasizes anatomic relationships to the brainstem and cranial nerves, common imaging pitfalls, and how tumor location and biology influence extent of resection, prognosis, and adjuvant therapy. Spinal Ependymomas This session on Spinal Ependymomas focuses on their clinical presentation, imaging features, and surgical management, discussed through real neurosurgical cases. The discussion highlights key anatomic considerations, tumor–cord relationships, extent of resection, and postoperative outcomes, with emphasis on how these factors influence neurologic preservation and long-term prognosis. Myxopapillary Ependymoma & Subependymoma This session covers Myxopapillary Ependymoma and Subependymoma, highlighting their distinct anatomic locations, imaging features, and surgical considerations, discussed in a concise manner. The discussion emphasizes tumor behavior, extent of resection, recurrence risk, and long-term outcomes, with a focus on how these typically indolent ependymal tumors differ from other spinal and intracranial neoplasms.

Coming Soon.

Neurofibromatosis Type 1, Type 2, and Schwannomatosis Q. What is Neurofibromatosis? Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum. Neurofibromatosis Type 1 (NF1) Q. What is the genetic basis of NF1? NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation. Q. What is the inheritance pattern? NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations. Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)? Diagnosis requires two or more of the following: 1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal). 2. Two or more neurofibromas of any type, or one plexiform neurofibroma. 3. Axillary or inguinal freckling (Crowe sign). 4. Optic pathway glioma. 5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography). 6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone. 7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.) Q. What are the additional supportive (nonessential) features of NF1? Macrocephaly, short stature, and learning disabilities or ADHD. Seizures, developmental delay, or autism spectrum traits. Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia. Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease). Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma). Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas. Choroidal hamartomas visible on near-infrared OCT. Elephantiasis neuromatosa from plexiform neurofibroma overgrowth. Q. What are the clinical features of NF1? Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas. Ophthalmic: Lisch nodules, optic pathway glioma. Neurologic: learning disability, ADHD, seizures, headaches. Skeletal: scoliosis, bone dysplasia. Tumors: MPNST, astrocytoma, pheochromocytoma. Q. What are the radiologic findings? MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions. Q. How is NF1 managed? Observation for asymptomatic lesions. Surgical excision for symptomatic or disfiguring neurofibromas. Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome. Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic. MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy. Q. What is the prognosis? Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis. Neurofibromatosis Type 2 (NF2) Q. What is the genetic basis of NF2? NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation. Q. What is the inheritance pattern? NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic. Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)? Diagnosis can be made by: 1. Bilateral vestibular schwannomas, or 2. A first-degree relative with NF2-related schwannomatosis plus either - unilateral vestibular schwannoma, or - any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract. 3. NF2 pathogenic variant in blood or tumor, with compatible clinical features. Q. What are supportive clinical features of NF2? Bilateral vestibular schwannomas (pathognomonic). Multiple meningiomas (intracranial and spinal). Spinal ependymomas and schwannomas. Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas. Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots). Cranial neuropathies and hearing loss as early symptoms. Family history of early-onset hearing loss or CNS tumors. Q. What is the typical age of presentation? Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2. Q. What are the imaging findings? MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas. MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas. Q. How is NF2 managed? MRI surveillance (brain and spine every 12–24 months). Microsurgery or radiosurgery for symptomatic tumors. Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing. Rehabilitation with cochlear or brainstem implants for hearing loss. Genetic counseling for family. Q. What is the prognosis? Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression. Schwannomatosis Q. What is schwannomatosis? Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum. Q. What is the genetic basis? Three defined molecular subtypes: 1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12). 2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23). 3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23). Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell. Q. What is the inheritance pattern? Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic. Q. What are the diagnostic criteria (2022 update)? Clinical diagnosis: - Two or more non-intradermal schwannomas confirmed histologically. - No bilateral vestibular schwannomas on MRI. - No constitutional NF2 mutation or first-degree relative with NF2. Molecular diagnosis: - Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement. Q. What are the clinical features? Chronic or paroxysmal pain (hallmark symptom). Palpable nerve masses along peripheral or spinal nerves. No vestibular or hearing symptoms. Minimal skin lesions, no café-au-lait spots or Lisch nodules. May have mononeuropathies or focal weakness due to nerve compression. Q. What are the radiological features? MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas. Diffusion and contrast help differentiate from meningiomas or neurofibromas. Q. What are the histopathological findings? Typical schwannoma pattern: - Antoni A and Antoni B areas. - Verocay bodies in Antoni A. - Strong S-100 positivity. - No entrapped axons (unlike neurofibroma). Q. What are the differences among genetic subtypes? SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas. LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma. NF2-related: mosaic or milder NF2 phenotype. Q. How is schwannomatosis managed? Surgical resection of symptomatic schwannomas. Pain control with neuropathic agents and nerve blocks. MRI surveillance every 2–3 years. Genetic counseling for family. No established drug therapy; bevacizumab is ineffective except in NF2-related cases. Q. What is the prognosis? Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries. Histologic Discussion: Schwannoma vs Neurofibroma Q. How do schwannoma and neurofibroma differ? Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy. Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk. Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma. Q. What are Antoni A and Antoni B areas, and Verocay bodies? Antoni A areas are hypercellular and organized with nuclear palisading. Antoni B areas are hypocellular, myxoid, and loosely arranged. Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma. Q. What is segmental or mosaic NF? A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring. Q. What is plexiform neurofibroma and why is it significant? Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST. Q. What is MPNST? A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance. Genetic mechanisms of tumorigenesis: Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation. NF1: RAS pathway dysregulation. NF2: loss of contact inhibition via merlin deficiency. Follow-up protocols: NF1 – annual BP, neuro and eye exams, MRI if symptomatic. NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly. Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring. Final recall summary: NF1 = Peripheral + Pigmentary. NF2 = Central + Vestibular. Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.

Petrosal Approach Revisited | Part 2 Refining anatomical concepts and operative strategy for accessing petroclival lesions with focus on petrous bone landmarks, cranial nerve relationships, and skull base exposure. Sylvian Fissure Splitting Guide Master Sylvian fissure splitting with a clear, step-by-step approach. This video breaks down microsurgical anatomy, safe dissection planes, arachnoid opening techniques, and key operative landmarks. Case-Based Approach to Frontal Lesions | Part 2 Discussion on bifrontal and subfrontal approaches, using olfactory groove meningioma as the key example. Topics include imaging, tumor extension, surgical corridor planning, and risk anticipation. Case-Based Approach to Frontal Lesions | Part 1 Frontal lesions can present with subtle cognitive, behavioral, motor, language, seizure, or executive function changes. This session simplifies the diagnostic reasoning process and highlights surgical considerations in real-world practice. Cranial Neurosurgical Approaches Pterional Craniotomy Learn the key surface landmarks, burr hole placement, bone flap design, sphenoid wing drilling, and surgical principles that make this approach essential for aneurysm surgery, skull base tumors, and transsylvian procedures. Petrous Bone Surgical Anatomy Essential anatomical landmarks for mastering skull base approaches, including anterior, posterior, and combined petrosal techniques. Includes guide for safe drilling and corridor development. Petrosal Approach | Part 1 Comprehensive guide to core anatomical concepts, surgical corridors, and operative strategy for one of the most versatile yet technically demanding skull base approaches.

Hemangioblastomas In this session of The Neurosurgical Case Room, we discuss the radiologic hallmarks, clinical presentation, vascular considerations, and decision-making in hemangioblastoma. In this session of The Neurosurgical Case Room, we focus on the management and operative strategy for hemangioblastoma, one of the most vascular tumors encountered in posterior fossa surgery. The discussion centers on surgical planning, approach selection, and the principle of en bloc resection to prevent uncontrolled bleeding. Key nuances such as preservation of venous drainage, sequential control of arterial feeders, and avoidance of internal debulking are emphasized. We also address decision-making in cerebellar lesions and the clinical context of Von Hippel–Lindau disease.

Excellence Without Borders. The Neurosurgical Mindset. A global platform for neurosurgical thinking, training, and conversations. Explore our Clinical Library Global Neurosurgery Conversations The Neurosurgical Case Room A Space for the Neurosurgical Mindset The Neurosurgical Case Room is an initiative by two Pakistani neurosurgeons, Dr. Kanwal Ali and Dr. Etizaz Ahmed, aimed at building a neurosurgical community that transcends geography and resources. In just eight months, TNCR has grown to a WhatsApp community of 780+ neurosurgeons and residents across 65+ countries, alongside 90+ interactive sessions and more than 39,000 cumulative YouTube views since January 2026. Global Neurosurgery Conversations A flagship series featuring neurosurgeons from across the world, exploring training, surgical philosophy, and the mindset behind excellence. View All Conversations → A growing collection of interactive Zoom-based video sessions designed primarily for neurosurgical residents, combining focused teaching and case-based discussion. Each session aims to cover a specific topic comprehensively, from core concepts to clinical application, providing structured, practical learning throughout residency. Cranial Core neurosurgical principles and operative thinking. Clinical Library Spine Degenerative, trauma, and surgical decision-making. Explore Clinical Library Anatomy Approaches, anatomy, and high-stakes judgment. TNCR Rapid Review TNCR Review Notes are concise, exam-focused revision notes written primarily for FCPS and MS Neurosurgery exit examination candidates. They are also designed to support neurosurgery residents at all stages of training who need a structured resource for quick review and reinforcement of key concepts. These notes are intended as a supplement to, not a replacement for, standard neurosurgical textbooks and primary literature. The Team Built by neurosurgeons. Supported by a growing global network. Meet the Team Enter the Case Room Get early access to conversations, curated clinical content, and upcoming releases. Email Address* Join Now

Neurofibromatosis Type 1, Type 2, and Schwannomatosis Q. What is Neurofibromatosis? Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum. Neurofibromatosis Type 1 (NF1) Q. What is the genetic basis of NF1? NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation. Q. What is the inheritance pattern? NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations. Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)? Diagnosis requires two or more of the following: 1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal). 2. Two or more neurofibromas of any type, or one plexiform neurofibroma. 3. Axillary or inguinal freckling (Crowe sign). 4. Optic pathway glioma. 5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography). 6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone. 7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.) Q. What are the additional supportive (nonessential) features of NF1? Macrocephaly, short stature, and learning disabilities or ADHD. Seizures, developmental delay, or autism spectrum traits. Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia. Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease). Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma). Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas. Choroidal hamartomas visible on near-infrared OCT. Elephantiasis neuromatosa from plexiform neurofibroma overgrowth. Q. What are the clinical features of NF1? Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas. Ophthalmic: Lisch nodules, optic pathway glioma. Neurologic: learning disability, ADHD, seizures, headaches. Skeletal: scoliosis, bone dysplasia. Tumors: MPNST, astrocytoma, pheochromocytoma. Q. What are the radiologic findings? MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions. Q. How is NF1 managed? Observation for asymptomatic lesions. Surgical excision for symptomatic or disfiguring neurofibromas. Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome. Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic. MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy. Q. What is the prognosis? Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis. Neurofibromatosis Type 2 (NF2) Q. What is the genetic basis of NF2? NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation. Q. What is the inheritance pattern? NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic. Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)? Diagnosis can be made by: 1. Bilateral vestibular schwannomas, or 2. A first-degree relative with NF2-related schwannomatosis plus either - unilateral vestibular schwannoma, or - any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract. 3. NF2 pathogenic variant in blood or tumor, with compatible clinical features. Q. What are supportive clinical features of NF2? Bilateral vestibular schwannomas (pathognomonic). Multiple meningiomas (intracranial and spinal). Spinal ependymomas and schwannomas. Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas. Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots). Cranial neuropathies and hearing loss as early symptoms. Family history of early-onset hearing loss or CNS tumors. Q. What is the typical age of presentation? Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2. Q. What are the imaging findings? MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas. MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas. Q. How is NF2 managed? MRI surveillance (brain and spine every 12–24 months). Microsurgery or radiosurgery for symptomatic tumors. Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing. Rehabilitation with cochlear or brainstem implants for hearing loss. Genetic counseling for family. Q. What is the prognosis? Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression. Schwannomatosis Q. What is schwannomatosis? Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum. Q. What is the genetic basis? Three defined molecular subtypes: 1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12). 2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23). 3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23). Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell. Q. What is the inheritance pattern? Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic. Q. What are the diagnostic criteria (2022 update)? Clinical diagnosis: - Two or more non-intradermal schwannomas confirmed histologically. - No bilateral vestibular schwannomas on MRI. - No constitutional NF2 mutation or first-degree relative with NF2. Molecular diagnosis: - Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement. Q. What are the clinical features? Chronic or paroxysmal pain (hallmark symptom). Palpable nerve masses along peripheral or spinal nerves. No vestibular or hearing symptoms. Minimal skin lesions, no café-au-lait spots or Lisch nodules. May have mononeuropathies or focal weakness due to nerve compression. Q. What are the radiological features? MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas. Diffusion and contrast help differentiate from meningiomas or neurofibromas. Q. What are the histopathological findings? Typical schwannoma pattern: - Antoni A and Antoni B areas. - Verocay bodies in Antoni A. - Strong S-100 positivity. - No entrapped axons (unlike neurofibroma). Q. What are the differences among genetic subtypes? SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas. LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma. NF2-related: mosaic or milder NF2 phenotype. Q. How is schwannomatosis managed? Surgical resection of symptomatic schwannomas. Pain control with neuropathic agents and nerve blocks. MRI surveillance every 2–3 years. Genetic counseling for family. No established drug therapy; bevacizumab is ineffective except in NF2-related cases. Q. What is the prognosis? Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries. Histologic Discussion: Schwannoma vs Neurofibroma Q. How do schwannoma and neurofibroma differ? Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy. Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk. Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma. Q. What are Antoni A and Antoni B areas, and Verocay bodies? Antoni A areas are hypercellular and organized with nuclear palisading. Antoni B areas are hypocellular, myxoid, and loosely arranged. Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma. Q. What is segmental or mosaic NF? A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring. Q. What is plexiform neurofibroma and why is it significant? Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST. Q. What is MPNST? A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance. Genetic mechanisms of tumorigenesis: Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation. NF1: RAS pathway dysregulation. NF2: loss of contact inhibition via merlin deficiency. Follow-up protocols: NF1 – annual BP, neuro and eye exams, MRI if symptomatic. NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly. Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring. Final recall summary: NF1 = Peripheral + Pigmentary. NF2 = Central + Vestibular. Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.

Hydrocephalus Hydrocephalus is defined as an abnormal accumulation of cerebrospinal fluid (CSF) within the ventricular system of the brain, resulting from obstruction of CSF flow, impairment of CSF absorption, or, rarely, CSF overproduction. The pathophysiology reflects either proximal stagnation of CSF, failure of reabsorption, or mechanical blockage anywhere between the ventricular system and the arachnoid granulations. Q. What is the epidemiology of hydrocephalus? Hydrocephalus affects approximately 1–1.5% of the general population. Congenital hydrocephalus has an incidence of 0.9–1.8 per 1000 births, with an overall reported range from 0.2–3.5 per 1000. It may be detected antenatally, at birth, or in the early months of life. Hydrocephalus occurs across all age groups, with congenital and infantile forms being the most common early-life presentations, whereas normal-pressure hydrocephalus predominates in older adults. Q. How do you classify hydrocephalus? Hydrocephalus can be classified broadly into functional, etiologic, pressure-based, and morphologic categories. A. Functional Classification: Obstructive (non-communicating) hydrocephalus: CSF flow is blocked within the ventricular system before reaching the arachnoid granulations. Ventricular enlargement occurs proximal to the obstruction. Communicating (non-obstructive) hydrocephalus: Ventricular pathways remain patent, but CSF absorption at the arachnoid villi is impaired. CSF overproduction: Rare; occurs mainly in choroid plexus tumors. Absorption is usually partially compensatory unless flow is obstructed. B. Etiologic Classification Congenital Acquired Post-infectious Post-hemorrhagic Neoplastic Vascular Genetic (e.g., X-linked hydrocephalus) C. Pressure-Based Classification Normal-pressure hydrocephalus Hydrocephalus ex vacuo Long-standing overt ventriculomegaly in adults (LOVA) D. Morphologic (Radiologic) Classification Univentricular enlargement (e.g. entrapped 4th ventricle) Biventricular enlargement (e.g. obstruction at foramen of monro) Triventricular hydrocephalus (e.g. aqueductal stenosis) Communicating ventriculomegaly (secondary to IVH or meningitis, e.t.c.) Entrapped fourth ventricle Q. What are the etiologies of hydrocephalus? A. Congenital Causes Chiari II malformation with myelomeningocele Chiari I malformation Primary congenital aqueductal stenosis Secondary aqueductal gliosis from intrauterine events Dandy–Walker malformation (atresia of Magendie and Luschka) X-linked hydrocephalus (L1CAM mutation) Encephaloceles Other developmental anomalies affecting posterior fossa CSF pathways or foraminal patency B. Acquired Causes Infectious: bacterial meningitis, TB meningitis, cysticercosis Hemorrhagic: intraventricular hemorrhage (IVH), subarachnoid hemorrhage (SAH) Neoplastic: tumors obstructing CSF flow (colloid cyst, medulloblastoma, ependymoma, suprasellar tumors) Postoperative: especially after posterior fossa tumor excision or intraventricular surgery Traumatic: post-traumatic SAH or IVH; scarring of subarachnoid pathways Neurosarcoidosis: granulomatous obstruction of CSF pathways C. Vascular Causes Arteriovenous malformations Vein of Galen aneurysmal malformation (VGAM) D. Functional/Physiological Causes Constitutional or benign ventriculomegaly Arrested or compensated hydrocephalus (non-progressive) Q. What are the special forms of hydrocephalus? Special variants include: Hydrocephalus ex vacuo LOVA (long-standing overt ventriculomegaly in adults) External hydrocephalus (benign external hydrocephalus) Entrapped fourth ventricle Arrested hydrocephalus Triventricular hydrocephalus Normal-pressure hydrocephalus Q. What are the clinical features of hydrocephalus in older children and adults? Older children and adults typically present with signs attributable to increased intracranial pressure and disruption of periventricular white matter tracts. Headache Nausea and vomiting Papilledema Impaired concentration and cognitive slowing Gait instability Parinaud’s syndrome from tectal pressure Sixth nerve palsy from elevated ICP Personality changes or irritability Urinary incontinence (late) Blurred vision and visual field defects from chronic papilledema Slow ventricular enlargement may present subtly, with cognitive and gait changes preceding overt ICP symptoms. Q. What are the clinical features of hydrocephalus in infants and young children? Symptoms include: Irritability Excessive crying Poor head control Feeding difficulties Vomiting Failure to thrive Developmental delay Signs include: Progressive macrocephaly with OFC crossing percentiles Bulging or tense anterior fontanelle Prominent scalp veins from reversed venous flow Frontal bossing McEwan’s sign: cracked-pot percussion note Setting sun sign: downward deviation of eyes from pressure on suprapineal recess Hyperreflexia Irregular respirations or apneic spells Sutural diastasis in chronic cases Q. How do you measure OFC and what findings suggest hydrocephalus? Technique: Place a non-stretchable measuring tape over the supraorbital ridge anteriorly and around the most prominent point of the occiput posteriorly. Ensure the tape is snug and hair is flattened. Repeat twice; if measurements differ by more than 2 mm, take a third and average the closest two. Abnormal Findings: OFC growth exceeding 1.25 cm per week OFC above 2 SD for age Head circumference rising across percentile curves Persistent macrocephaly relative to overall growth pattern OFC out of proportion to facial/cranial growth Q. What are the radiologic features of hydrocephalus? The radiologic features can be divided into: A. Acute Hydrocephalus: Reflects sudden obstruction or acute failure of CSF resorption. 1. Temporal horn enlargement ≥ 2 mm Earliest and most sensitive sign. Normally TH is barely visible. Criteria for acute hydrocephalus: TH ≥ 2 mm and fissures/sulci not visible OR TH ≥ 2 mm + FH/ID > 0.5 (not Evans index) 2. Ballooning of frontal horns: “Mickey Mouse” ventricles 3. Widening of the third ventricle: Should normally be slit-like 4. Periventricular low density on CT: Represents transependymal interstitial edema due to stasis of flow around ventricles 5. Periventricular T2 hyperintensity on MRI: Represents CSF stasis rather than actual CSF diffusion through ependyma. 6. Obstructive patterns: Dilated ventricles proximal to the block, for e.g. colloid cyst can cause biventricular enlargement 7. Loss of cortical sulci and cisterns (effacement): Due to acute rise in ICP 8. Upward bowing of corpus callosum from ventricular expansion B. Chronic Hydrocephalus – Radiologic Features Chronic hydrocephalus produces characteristic long-standing changes due to sustained ventricular expansion and cranial remodeling: Beaten copper or beaten silver cranium on skull radiographs Third ventricular downward ballooning into the sella Erosion or empty sella from chronic pressure Temporal horns less prominent than in acute states Macrocrania (>98th percentile OFC) Corpus callosum thinning and upward bowing Widened sutures, delayed closure of fontanelles (infants) Cortical mantle thinning from longstanding ventricular expansion Smooth, rounded ventricular contours Often lack of acute transependymal edema Q. What is the Evans Index and how is it interpreted? Evans Index is the ratio of the maximal frontal horn width divided by the maximal biparietal diameter on the same axial CT or MRI slice. Evans Index >0.3 is considered indicating hydrocephalus. Evans Index <0.3 is usually normal (0.25 is considered a grey zone). Q. What are the limitations of the Evans Index? Evans Index is widely used but has several important limitations: The measurement varies with axial slice angle. Maximal biparietal diameter may not lie on the same slice as maximal frontal horn width. Underestimates pediatric hydrocephalus because occipital horns often enlarge more than frontal horns. Variability in the ratio may exceed actual structural differences. Thus, Evans Index alone should never be used as a sole diagnostic criterion. Q. What is McEwan’s sign? McEwan’s sign is a cracked-pot percussion sound produced when tapping the skull of an infant (mostly at anterior fontanelle) with marked hydrocephalus. It is caused by: Separation of sutures Thinning of cranial bones Increased resonance due to enlarged ventricles It is a classic sign of chronic infantile hydrocephalus. Q. What is external hydrocephalus, and how do you differentiate it from true hydrocephalus? External hydrocephalus, also known as benign external hydrocephalus (BESS), is a condition in which CSF accumulates in the subarachnoid spaces, predominantly over the frontal and frontoparietal convexities, due to delayed maturation of arachnoid villi. It is not obstructive or communicating hydrocephalus, and the ventricles maintain normal or only mildly increased diameter. Pathophysiology: Arachnoid granulations are immature in early infancy. CSF production is normal but absorption is temporarily reduced, thus CSF preferentially expands subarachnoid spaces instead of ventricles. As arachnoid villi mature (by 18–24 months), spaces normalize. Clinical Features: Occurs between 3 and 18 months of age. Macrocephaly with OFC typically above the 97th percentile. Development is normal or near normal. No symptoms of raised intracranial pressure. Positive family history of macrocephaly in some cases. Radiologic Features Enlarged frontal subarachnoid spaces, symmetrical. Interhemispheric fissure widened. Ventricles normal or minimally enlarged, not disproportionate. Cortical mantle thickness normal, which is a major point of differentiation. Cortical vein sign: visible cortical veins crossing the widened subarachnoid spaces, helping differentiate from subdural effusion. Differentiation from True Hydrocephalus External hydrocephalus: Subarachnoid enlargement > ventricular enlargement Normal cortex thickness No sulcal effacement Normal intracranial pressure No transependymal edema Stable OFC growth pattern Resolves spontaneously True hydrocephalus: Ventricular dilation > subarachnoid space dilation Sulcal effacement Periventricular edema Signs of raised ICP Progressive symptoms Requires CSF diversion Course and Prognosis Peaks around 6–12 months Resolves spontaneously by age 2 No long-term neurological deficit expected Management: Observation only Serial OFC and developmental monitoring No role for surgical intervention Imaging only if symptoms change Q. What is arrested hydrocephalus? Arrested hydrocephalus refers to a non-progressive, compensated form of ventriculomegaly in which CSF dynamics reach a steady state. The ventricles are enlarged, but CSF pressure is stable, and the patient has no clinical or radiologic evidence of progression. Pathophysiology: Initial hydrocephalus (congenital, post-infectious, post-hemorrhagic) occurs. CSF absorption pathways partially or completely recover. Ventricular enlargement remains but does not progress. Brain adapts via decreased CSF production, enhanced alternative absorption, and tissue compliance adjustments. Clinical Features: Asymptomatic or minimally symptomatic Normal OFC trajectory in infants No vomiting, irritability, papilledema, or headache Mild developmental delays may persist from initial insult, but no ongoing decline No gait instability or cognitive worsening in older children Radiologic Features Stable ventricular size on sequential CT/MRI No transependymal edema Normal periventricular signal Stable corpus callosum morphology No progressive skull changes In infants: fontanelle and sutures may have adapted and remain static Diagnosis: Requires three components. Clinical stability Radiological stability on serial imaging Absence of raised ICP features Triggers for Reactivation Even stable hydrocephalus can “reactivate”: Meningitis Trauma (sometimes even mild) New hemorrhage Pubertal brain growth Sudden changes in CSF absorption Management: Observation only if fully compensated Serial OFC in infants Neurological and developmental monitoring Imaging every 6–12 months initially Intervention only if reactivation occurs Treatment of Reactivation: ETV if obstructive pattern develops VP shunt if communicating or absorption failure recurs Arrested hydrocephalus should never be shunted unless clearly decompensating, as unnecessary shunting may precipitate subdural hematomas and overdrainage-related complications. Q. What is an entrapped fourth ventricle? Entrapped fourth ventricle is a condition where the fourth ventricle becomes isolated due to obstruction of both its inlet (aqueduct) and outlets (foramina of Magendie and Luschka), leading to progressive dilation of the fourth ventricle and compression of the brainstem and cerebellum. Pathophysiology: Two simultaneous blocks: 1. Aqueductal obstruction: Prevents CSF flow from third to fourth ventricle. Often secondary to gliosis, hemorrhage, or infection. 2. Outlet obstruction Scarring of Magendie/Luschka caused by meningitis, arachnoiditis, or postoperative scarring. CSF continues to be produced by the choroid plexus inside the fourth ventricle, causing a closed compartment with progressive dilation. Etiology: Post-intraventricular hemorrhage Post-meningitic or TB meningitis scarring Postoperative scarring after posterior fossa surgery Aqueductal gliosis Arachnoiditis VP shunting of supratentorial ventricles, leading to collapse above and pressure buildup below Clinical Features: Symptoms are due to brainstem and cerebellar compression: Ataxia and truncal imbalance Dysarthria and dysphagia Horizontal or vertical gaze palsies Nystagmus Irritability or lethargy in infants Respiratory irregularity or apneic spells New neurological deficits after VP shunt insertion (classic presentation) Head circumference may be normal if supratentorial ventricles are decompressed by a shunt Radiological Features: Isolated dilation of the fourth ventricle Supratentorial ventricles normal or small (post-shunting) Fourth ventricle ballooned posteriorly and inferiorly Brainstem flattened and compressed anteriorly Vermis displaced posteriorly Sagittal MRI best demonstrates outlet and aqueductal obstruction No transependymal edema unless chronic Management Options: 1. Endoscopic Aqueductoplasty Removes glial scar tissue from aqueduct. Balloon dilation performed after perforation. Useful when aqueduct obstruction is the primary problem. 2. Aqueductal Stenting Prevents restenosis of newly opened aqueduct. Required in cases of thick gliosis or scarring. Provides long-lasting patency. 3. Fourth Ventricular Shunting Fourth ventriculoperitoneal shunt Fourth ventriculopleural shunt Indicated when outlet obstruction is absolute or endoscopy is not feasible. Access via midline suboccipital route or transforaminal approach. 4. Endoscopic Third Ventriculostomy (ETV) Useful only if aqueduct is obstructed but outlets are patent after surgical restoration. Provides shunt-free diversion of CSF through the third ventricular floor. 5. Posterior Fossa Surgery: Rarely used and reserved for dense arachnoiditis not amenable to endoscopy or shunting. Follow-up: MRI to confirm reduction in fourth ventricular size Neurological monitoring Shunt surveillance if implanted Q. What is X-linked hydrocephalus? X-linked hydrocephalus is a genetic, congenital, severe obstructive hydrocephalus caused by L1CAM gene mutations on the X chromosome. It is inherited in an X-linked recessive pattern, primarily affecting males. Genetic Basis L1CAM encodes an adhesion molecule critical for neuron migration and axon pathfinding. Mutations lead to: Defective neuronal migration Abnormal axonal guidance Midline structural abnormalities Aqueductal stenosis development Structural Abnormalities: Aqueductal stenosis (congenital or acquired from gliosis) Corpus callosum agenesis or hypoplasia Hydrocephalus with massive ventriculomegaly Corticospinal tract malformations Optic nerve hypoplasia in some cases Periventricular heterotopias may occur Clinical Features: Severe hydrocephalus detected antenatally or at birth Macrocephaly Adducted thumbs (classic hallmark of L1 syndrome) Spasticity Developmental delay Seizures may occur Feeding difficulties Variable cognitive impairment depending on structural severity Radiologic Features: Marked triventricular obstructive hydrocephalus Narrowed or absent aqueduct Enlarged lateral and third ventricles Thin cortical mantle if severe Corpus callosum agenesis or hypoplasia Midbrain structural deformities Possible periventricular leukomalacia from chronic stretch Diagnosis: MRI brain Genetic testing confirming L1CAM mutation Family history analysis Management: 1. Ventriculoperitoneal (VP) Shunt: Mainstay of treatment. Required early in life to prevent brain injury 2. ETV: Often has low success because of: Concomitant cisternal abnormalities Poor subarachnoid compliance Complex aqueductal malformations 3. Supportive Management: Physiotherapy for spasticity, seizure management, and developmental therapies Prognosis: Depends on severity of structural abnormalities, timing of intervention, and presence of associated neurological deficits. Q. What are the complications of untreated hydrocephalus? Neurological Complications: Developmental delay Cognitive impairment Learning difficulties Behavioral deterioration Motor dysfunction (spasticity, hemiparesis, gait abnormalities) Visual impairment due to chronic papilledema Seizures Structural Complications Severe macrocephaly (infants) Skull deformities Cortical thinning and permanent loss of cortical mantle Herniation syndromes in acute obstructive hydrocephalus Systemic Complications: Feeding difficulties Respiratory instability Apneic spells End-stage: cardiorespiratory arrest Untreated hydrocephalus leads to permanent brain injury and is fatal. Q. How do you manage hydrocephalus? A. Temporizing Measures External Ventricular Drain (EVD): Immediate CSF diversion in acute obstructive hydrocephalus (IVH, SAH, tumors, postoperative). Used to stabilize ICP before definitive management. B. Definitive Surgical Procedures 1. Ventriculoperitoneal (VP) Shunt Most common definitive treatment Indications: communicating hydrocephalus, post-infectious hydrocephalus, post-hemorrhagic hydrocephalus, failed ETV, NPH Programmable valves used to reduce overdrainage risks 2. Endoscopic Third Ventriculostomy (ETV) Now taken as First-line for obstructive hydrocephalus Indications: congenital aqueductal stenosis, triventricular obstruction, Chiari-related hydrocephalus Avoids shunt dependence Success dependent on age, etiology, cisternal anatomy 3. ETV with Choroid Plexus Cauterization (ETVCPC) Effective in infants Increases ETV success by reducing CSF production Especially beneficial in spina bifida and complex obstructive etiologies 4. Fourth Ventricular Shunting Indicated for entrapped fourth ventricle Options: VP or VPL shunts with catheter positioned into the fourth ventricle 5. Lumboperitoneal Shunt Used in communicating hydrocephalus with small ventricles Useful in NPH when ventricles are not dilated enough for ventricular catheter placement C. Principles of Management Treat underlying cause (e.g., tumor, infection) Avoid rapid decompression after SAH/IVH to prevent rebleeding Ensure sterile technique to prevent shunt infections Careful valve selection and postoperative monitoring D. Postoperative Follow-up Shunt patency assessment Serial imaging Monitoring for overdrainage (subdural hematoma), underdrainage, infection Neurodevelopmental assessment in children Regular ETV success evaluation (ETVSS considerations)

Coming Soon.

TNCR RAPID REVIEW Please note that these review notes were primarily developed on the pattern of Exit Exams for FCPS and MS Neurosurgery. They are not a replacement for textbooks, but a brilliant way for last minute revision. Congenital Cranial Tumors & Tumor-like Lesions Vascular Infections Spine Spinal Tumors Trauma Miscellaneous